Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Sun Pharma’s INSPIRE-1 and INSPIRE-2 studies met their primary endpoint at Week 24, with Ilumya 100 mg demonstrating superior efficacy over placebo in treating active psoriatic arthritis.

While IL-17 blocking agents are linked to an increased risk for candidiasis, bimekizumab, which blocks two proteins ...

Discover effective treatments for psoriatic arthritis, with expert tips on managing symptoms, reducing inflammation, and improving joint health for a better quality of life.

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Synovitis is significantly more likely among patients with psoriasis, and it is more likely among those with PsA than PsO.

August Campaign Highlights Total Wellness for Over 8 Million in the U.S. with Psoriasis ALEXANDRIA, VA, UNITED STATES, August 1, 2025 /EINPres ...